Sintilimab for early stage MSI-H/dMMR endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests the drug Sintilimab alone (without chemotherapy or radiation) for people with stage I or II endometrial cancer that has a specific genetic feature called MSI-H or dMMR. It may be an option if you want to avoid standard surgery to preserve your uterus or fertility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stage I or II endometrial cancer (any common type).
- Your tumor has been tested and shows a specific DNA repair problem called MSI-H or dMMR.
- You have at least one tumor that can be measured on a scan.
- You are in good general health (ECOG 0 or 1) and expected to live at least 12 months.
- You wish to avoid surgery to preserve your uterus or fertility, or you cannot have standard surgery because of other health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor) and progesterone hormone therapy to treat early-stage, MMR-deficient endometrial cancer while preserving fertility. It may help young women who want to keep the option to have children in the future.
This trial tests the drug sintilimab combined with a specific radiation schedule to treat rectal cancer that is MSI-H or dMMR (tumor DNA repair/instability markers). It may help shrink the tumor and improve outcomes when standard options are limited or not yet started.
This trial tests a combination of two drugs – fruquintinib (a pill that targets blood vessels feeding tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer) – for people with advanced endometrial cancer that has already been treated with platinum chemotherapy. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests an immunotherapy combination (iparomlimab and tuvonralimab) for patients with a specific type of endometrial cancer that has a high number of gene mutations (called dMMR or MSI-H). The goal is to shrink or eliminate the tumor so surgery may not be needed.
This trial tests how many cycles of the immunotherapy drug sintilimab given before surgery help treat colorectal cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). It is for locally advanced cancer that has not spread to other parts of the body.
This trial tests a drug called dostarlimab (an immunotherapy) given before surgery for early-stage endometrial cancer that has a specific genetic feature (MMRd/MSI-H). The goal is to see if the drug can shrink or eliminate the cancer before standard surgery.
Hear when a new MMRd Endometrial Cancer of Stage I~II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.